ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)

被引:11
|
作者
Vinik, Aaron
Wolin, Edward M.
Audry, Helene
Gomez-Panzani, Edda L.
机构
[1] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Ipsen, Boulougne Billancourt, France
关键词
D O I
10.1200/jco.2014.32.3_suppl.268
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
268
引用
收藏
页数:1
相关论文
共 50 条
  • [1] ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Gomez-Panzani, E.
    Vinik, A.
    Wolin, E.
    Audry, H.
    [J]. NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 271 - 271
  • [3] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients With Carcinoid Syndrome (CS)
    Duchateau, Luc
    Lescrauwaet, Benedicte
    Blot, Koenraad
    Liyanage, Nilani
    Ray, David
    Lowenthal, Susan Pitman
    Braun, Stephan
    Mirakhur, Beloo
    [J]. PANCREAS, 2018, 47 (03) : 338 - 338
  • [5] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
    Duchateau, L.
    Lescrauwaet, B.
    Blot, K.
    Liyanage, N.
    Ray, D.
    Lowenthal, S. P.
    Braun, S.
    Mirakhur, B.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 194 - 194
  • [6] Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
    Fisher, G. A., Jr.
    Wolin, E.
    Kunz, P. L.
    Liyanage, N.
    Mirakhur, B.
    Lowenthal, S. Pitman
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study
    Fisher, George A., Jr.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S457 - S458
  • [8] Long-Term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients With Carcinoid Syndrome (CS): The ELECT Long-Term Open-label Extension
    Vinik, Aaron
    Fisher, George, Jr.
    Kunz, Pamela
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Pommier, Rodney
    Shaheen, Montaser
    Wolin, Edward
    [J]. PANCREAS, 2017, 46 (03) : 437 - 437
  • [9] Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study
    Wolin, Edward M.
    Fisher, George A., Jr.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Mirakhur, Beloo
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S468 - S468
  • [10] Lanreotide Autogel/Depot (LAN) in Patients With Advanced Bronchopulmonary (BP) Neuroendocrine Tumors (NETs): Results From the Phase 3 SPINET Study
    Reidy-Lagunes, Diane
    Horsch, Dieter
    Singh, Simron
    Caplin, Martyn E.
    Ferone, Diego
    Wolin, Edward M.
    Capdevila, Jaume
    Buikhuisen, Wieneke
    Raderer, Markus
    Dansin, Eric
    Grohe, Christian
    Houchard, Aude
    Truong-Thanh, Xuan-Mai
    Baudin, Eric
    [J]. PANCREAS, 2022, 51 (03) : E37 - E38